Clinical trials: Age Related Maculopathy
Age-related Macular Degeneration, Pigment Epithelial Detachment
Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments
Patients with neovascular Age-related macular degeneration (AMD) and the particular feature of pigment epithelial detachments (PEDs) were not studied in the Phase III trials for ranibizumab (Lucentis).
- Conditions
- Age-related Macular Degeneration, Pigment Epithelial Detachment, Neovascular Macular Degeneration, Wet Macular Degeneration
- Trial name
- DETAIL (NCT00590694)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Pacific Eye Associates
Dry Eye Syndromes, Age-Related Macular Degeneration
Preventive TREatment of Dry Eye in Patients Receiving Repeated Intravitreal Injections for Age-related Macular Degeneration
Age-related macular degeneration (AMD) is the 1st cause of visual impairment after the age of 50. Its most aggressive form, wet AMD, requires regular intravitreal injections (IVI) spaced 4 to 8 weeks apart usually depending on…
- Trial name
- TREDIA (NCT06174181)
- Testing
- Preservative-free ophtalmic lubricant emulsion, Routine treatment
- Where
- 2 sites in France
- Volunteers
- 42 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
Age-related Macular Degeneration
Omega 6:Omega 3 Ratio and Progression of Age-related Macular Degeneration (AMD).
Docosahexaenoic acid (DHA) supplementation has been shown to prevent specific age-related changes in the retina through biochemical and functional evaluations, but it is unclear whether increased DHA intake-reflected through…
- Trial name
- NCT00987129
- Where
- 3 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Yves Sauve
Neovascular Age-related Macular Degeneration
Pegcetacoplan (APL-2) in Neovascular AMD
Safety Assessment of Pegcetacoplan in Patients with Neovascular AMD
- Trial name
- NCT03465709
- Testing
- Pegcetacoplan
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Age Related Macular Degeneration
Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration
The purpose of this study is to determine if of combination therapy of intravitreal bevacizumab 4 days after the application of photodynamic therapy could improve the visual outcomes of patients with neovascular age related…
- Trial name
- NCT00347399
- Testing
- bevacizumab intravitreal injection, verteporfin photodynamic therapy
- Where
- Mexico
- Volunteers
- 25 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Retinitis Pigmentosa, Age-related Macular Degeneration
Visual and Functional Assessment in Low Vision Patients
Vision testing is a fundamental part of every optometry and ophthalmology assessment. Traditional vision testing charts are not able to measure vision below a certain level.
- Conditions
- Retinitis Pigmentosa, Age-related Macular Degeneration, Optic Nerve Pathology, Inherited Retinal Dystrophies
- Trial name
- NCT01876147
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Oxford
Macular Degeneration
Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)
Wet age-related macular degeneration is the most common cause of blind registration in the United Kingdom (UK). Standard treatment involves regular eye injections of a drug called ranibizumab (Lucentis).
- Trial name
- MERLOT (NCT01006538)
- Testing
- Epimacular Brachytherapy, Ranibizumab
- Where
- 24 sites in United Kingdom
- Volunteers
- 363 people
- Sponsor
- King's College Hospital NHS Trust
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion
This is a Phase I, multicenter, open-label, dose-escalation study conducted in two parts to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GenSci148 administered via intravitreal (IVT)…
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
- Trial name
- GenSci148-101 (NCT07817615)
- Testing
- GenSci148 Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig (EYE103) in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination…
- Trial name
- AMARONE (NCT05919693)
- Testing
- Remigromig
- Where
- 32 sites in United States, Argentina and 2 more
- Volunteers
- 33 people
- Sponsor
- EyeBiotech Ltd.
Macular Degeneration
Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration
Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and December 31…
- Trial name
- REVIEW (NCT01933152)
- Testing
- Ranibizumab
- Where
- Portugal
- Volunteers
- 137 people
- Sponsor
- Bayer
Neovascular Age-related Macular Degeneration
Gene Therapy for Wet AMD
FT-003 is a gene therapy product developed for the treatment of neovascular age-related macular degeneration (nAMD). Neovascular AMD is the main cause of blindness among elderly individuals.
- Trial name
- NCT05611424
- Testing
- FT-003
- Volunteers
- 18 people
- Sponsor
- Frontera Therapeutics
Wet Macular Degeneration
Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration
The objective of this pilot study is to evaluate the efficacy of intensive fixed monthly dosing of intravitreal Lucentis® (Ranibizumab) for the treatment of SRF and PED in neovascular AMD which is persistent to anti-VEGF…
- Trial name
- NCT02944227
- Testing
- Lucentis
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Hospital
Wet Age-related Macular Degeneration
Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD
The currently widely established and preferred protocol for the treatment of wet age-related macular degeneration includes a loading phase of three monthly injections without interim adaptation or treatment according to disease…
- Trial name
- SPARROW (NCT04932980)
- Testing
- Aflibercept, Brolucizumab, early treat and extend (T&E)
- Where
- Switzerland
- Volunteers
- 80 people
- Sponsor
- Berner Augenklinik
Age-Related Macular Degeneration
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal…
- Trial name
- NCT01944839
- Testing
- E10030, ranibizumab
- Where
- 115 sites in United States, Austria and 11 more
- Volunteers
- 619 people
- Sponsor
- Ophthotech Corporation
Age-Related Macular Degeneration
Size Progression of Macular Degeneration After Cataract Surgery
The purpose of this study was to find out if in patients with non-exudative age-related macular degeneration (AMD), randomly assigned to cataract surgery, any AMD size progression or progression to exudative AMD could be detected…
- Trial name
- NCT01165801
- Testing
- Cataract Surgery
- Where
- Austria
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
AMD, Age-Related Macular Degeneration
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
The objective of this study is to demonstrate the safety and effectiveness of the SING IMT (Smaller Incision New Generation Implantable Miniature Telescope) 3X implant in improving vision in patients with central vision…
- Trial name
- NCT04796545
- Testing
- SING IMT(TM) System, model NG SI IMT 3X
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 68 people
- Sponsor
- VisionCare, Inc.
Macular Degeneration
Noninvasive Imaging Biomarkers of Treatable Macrovascular Disease in Age-related Macular Degeneration.
The purpose of this prospective study is to investigate whether ophthalmic artery stenosis (narrowing of the ophthalmic artery) contributes to the development and progression of geographic atrophy (GA), an advanced form of dry…
- Trial name
- NCT07798323
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Scott Raymond
Geographic Atrophy, Age-Related Macular Degeneration
OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration
Othera Pharmaceuticals' Othera (OT)-551 antioxidant eye drop has the potential for chronic treatment of the dry form of age-related macular degeneration.
- Conditions
- Geographic Atrophy, Age-Related Macular Degeneration, AMD
- Trial name
- NCT00306488
- Testing
- OT-551 antioxidant eye drop
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Exudative Age-related Macular Degeneration
LUCAS (Lucentis Compared to Avastin Study)
Age-related macular degeneration (AMD) is the most common cause of blindness in individuals over 50 years of age. Bevacizumab and ranibizumab are two agents developed by the American pharmaceutical corporation Genentech, both of…
- Trial name
- LUCAS (NCT01127360)
- Testing
- Bevacizumab, Ranibizumab
- Where
- Norway
- Volunteers
- 420 people
- Sponsor
- Oslo University Hospital
Age Related Macular Degeneration, Choroidal Neovascularization
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
The study will be designed as a case control evaluation to compare the genetic profiles of three groups of patients categorized according to diagnosis.
- Conditions
- Age Related Macular Degeneration, Choroidal Neovascularization, Central Serous Chorioretinopathy
- Trial name
- NCT01880788
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Sequenom, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.